Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20462651 | 0.81 | TSHR (0.56) | SMN1; SMN2TSHRPOLBGLALMNA | |
| SCHEMBL19975948 | 0.80 | ALDH1A1 (0.48) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL28287659 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRPOLBGLALMNA | |
| SCHEMBL17773338 | 0.78 | SMN1; SMN2 (1.00) | SMN1; SMN2TSHRPOLBGLALMNA | |
| SCHEMBL19703868 | 0.78 | ALDH1A1 (0.42) | SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL20780403 | 0.77 | POLB (0.56) | SMN1; SMN2TSHRPOLBGLALMNA | |
| SCHEMBL8229950 | 0.77 | PKM (0.57) | SMN1; SMN2TSHRPOLBGLALMNA | |
| SCHEMBL179553 | 0.75 | POLB (0.53) | SMN1; SMN2TSHRPOLBGLALMNA | |
| SCHEMBL19975981 | 0.75 | ALDH1A1 (0.43) | SMN1; SMN2POLBLMNAALDH1A1NPSR1 | |
| SCHEMBL823974 | 0.74 | HTT (0.55) | SMN1; SMN2LMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, BMI1, EED | SMN1; SMN2 1780/4885TSHR 4018/4885POLB 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.